Achieve Life Sciences Inc (ACHV)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$6.49-0.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Achieve Life Sciences Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	17.75M
EPS	—	-0.212
Annual ending 2026-12-31
Revenue	—	4.5M
EPS	—	-1.46
Annual ending 2027-12-31
Revenue	—	35.42M
EPS	—	-0.678

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Stabilize executive leadership after recent departures	A supporting condition in Achieve Life Sciences Inc's published investment case. The stated target is No further key executive departures in next 4 quarters.	Under Pressure	Any additional departure of C-suite or President within next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve EPS towards -1.25 USD per share or better	The company beat Q1 2026 EPS expectations, showing progress managing losses.	Improving	EPS falls below -1.25 USD per share in 2026-Q4	Diluted EPS: $-0.80 per share FY2026-Q2; GAAP. Published target: >=-1.25 USD_PER_SHARE. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 11, 2026-0.8 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6ce23a85-e201-49ca-8c85-00bff6c2fe10. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Secure private placement funding of up to $354 million	Achieve Life Sciences aims to raise $354 million through private placement.	Intact	gross proceeds fall below $180 million by 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management closed a private placement of up to $354 million including $180 million upfront and $174 million from milestone warrants in 2026-Q1. This funding is intended to support the Phase 3 trial and commercialization. The trajectory is delivering as the financing closed and proceeds are available. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.68

$-0.49 → $-0.68 · observed estimates

FY2027 revenue$0.04B

$0.04B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.49	$36,881,500	9 / 10
2026-07-25	$-0.49	$36,881,500	9 / 10
2026-07-26	$-0.49	$36,881,500	9 / 10
2026-07-27	$-0.49	$36,881,500	9 / 10
2026-07-28	$-0.49	$36,881,500	9 / 10
2026-07-29	$-0.49	$36,881,500	9 / 10
2026-07-30	$-0.49	$36,881,500	9 / 10
2026-07-31	$-0.49	$36,881,500	9 / 10
2026-08-01	$-0.49	$36,881,500	9 / 10
2026-08-02	$-0.49	$36,881,500	9 / 10
2026-08-03	$-0.49	$36,881,500	9 / 10
2026-08-04	$-0.49	$36,881,500	9 / 10
2026-08-05	$-0.49	$36,881,500	9 / 10
2026-08-06	$-0.49	$35,619,550	9 / 11
2026-08-07	$-0.49	$35,619,550	9 / 11
2026-08-08	$-0.49	$35,619,550	9 / 11
2026-08-09	$-0.60	$35,619,550	10 / 11
2026-08-10	$-0.60	$35,619,550	10 / 11
2026-08-11	$-0.60	$35,619,550	10 / 11
2026-08-12	$-0.60	$35,619,550	10 / 11
2026-08-13	$-0.69	$35,619,550	10 / 11
2026-08-14	$-0.58	$39,181,530	7 / 8
2026-08-15	$-0.58	$39,181,530	7 / 8
2026-08-16	$-0.58	$39,181,530	8 / 8
2026-08-17	$-0.58	$39,181,530	8 / 8
2026-08-18	$-0.58	$39,181,530	8 / 8
2026-08-19	$-0.58	$39,181,530	8 / 8
2026-08-20	$-0.58	$39,181,530	8 / 8
2026-08-21	$-0.66	$35,227,478	8 / 8
2026-08-22	$-0.66	$35,227,478	8 / 8
2026-08-23	$-0.66	$35,227,478	8 / 8
2026-08-24	$-0.66	$35,227,478	8 / 8
2026-08-25	$-0.66	$35,227,478	8 / 8
2026-08-26	$-0.66	$35,227,478	8 / 8
2026-08-27	$-0.66	$35,227,478	8 / 8
2026-08-28	$-0.66	$35,227,478	8 / 8
2026-08-29	$-0.66	$35,227,478	8 / 8
2026-08-30	$-0.66	$35,227,478	8 / 8
2026-08-31	$-0.66	$35,227,478	8 / 8
2026-09-01	$-0.66	$35,227,478	8 / 8
2026-09-02	$-0.66	$35,227,478	8 / 8
2026-09-03	$-0.66	$35,227,478	8 / 8
2026-09-04	$-0.66	$35,227,478	8 / 8
2026-09-05	$-0.66	$35,227,478	8 / 8
2026-09-06	$-0.66	$35,227,478	8 / 8
2026-09-07	$-0.66	$35,227,478	8 / 8
2026-09-08	$-0.66	$35,227,478	8 / 8
2026-09-09	$-0.66	$35,227,478	8 / 8
2026-09-10	$-0.66	$35,227,478	8 / 8
2026-09-11	$-0.66	$35,227,478	8 / 8
2026-09-12	$-0.66	$35,227,478	8 / 8
2026-09-13	$-0.66	$35,227,478	8 / 8
2026-09-14	$-0.66	$35,227,478	8 / 8
2026-09-15	$-0.66	$35,227,478	8 / 8
2026-09-16	$-0.66	$35,227,478	8 / 8
2026-09-17	$-0.66	$35,227,478	8 / 8
2026-09-18	$-0.66	$35,227,478	8 / 8
2026-09-19	$-0.66	$35,227,478	8 / 8
2026-09-20	$-0.66	$35,227,478	8 / 8
2026-09-21	$-0.66	$35,227,478	8 / 8
2026-09-22	$-0.66	$35,227,478	8 / 8
2026-09-23	$-0.66	$35,227,478	8 / 8
2026-09-24	$-0.66	$35,227,478	8 / 8
2026-09-25	$-0.66	$35,227,478	8 / 8
2026-09-26	$-0.66	$35,227,478	8 / 8
2026-09-27	$-0.66	$35,227,478	8 / 8
2026-09-28	$-0.66	$35,227,478	8 / 8
2026-09-29	$-0.66	$35,227,478	8 / 8
2026-09-30	$-0.66	$35,227,478	8 / 8
2026-10-01	$-0.68	$35,424,980	9 / 9
2026-10-02	$-0.68	$35,424,980	9 / 9
2026-10-03	$-0.68	$35,424,980	9 / 9
2026-10-04	$-0.68	$35,424,980	9 / 9
2026-10-05	$-0.68	$35,424,980	9 / 9
2026-10-06	$-0.68	$35,424,980	9 / 9
2026-10-07	$-0.68	$35,424,980	9 / 9
2026-10-08	$-0.68	$35,424,980	9 / 9
2026-10-09	$-0.68	$35,424,980	9 / 9
2026-10-10	$-0.68	$35,424,980	9 / 9
2026-10-11	$-0.68	$35,424,980	9 / 9
2026-10-12	$-0.68	$35,424,980	9 / 9
2026-10-13	$-0.68	$35,424,980	9 / 9
2026-10-14	$-0.68	$35,424,980	9 / 9
2026-10-15	$-0.68	$35,424,980	9 / 9
2026-10-16	$-0.68	$35,424,980	9 / 9
2026-10-17	$-0.68	$35,424,980	9 / 9
2026-10-18	$-0.68	$35,424,980	9 / 9
2026-10-19	$-0.68	$35,424,980	9 / 9
2026-10-20	$-0.68	$35,424,980	9 / 9
2026-10-21	$-0.68	$35,424,980	9 / 9
2026-10-22	$-0.68	$35,424,980	9 / 9
2026-10-23	$-0.68	$35,424,980	9 / 9
2026-10-24	$-0.68	$35,424,980	9 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	11	0	0
2026-09-01	12	0	0
2026-10-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausSep 29

$18.00New observation · no comparable prior

$0$9.90$19.80

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stabilize executive leadership after recent departuresPublished status: Under Pressure
Improve EPS towards -1.25 USD per share or betterDiluted EPS: $-0.80 per share
Secure private placement funding of up to $354 millionDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-54.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Achieve Life Sciences Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative development-stage investment, not an established earnings compounder. Its thesis is on watch: recent financial performance is weak versus its industry cohort, though it has not freshly broken.

What's priced into Achieve Life Sciences Inc

The evidence does not provide a valuation level or specific market expectations, so whether the shares are cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not resolve the uncertainty around a loss-making business with elevated risk.

What the fundamentals likely do

Near term, losses may remain substantial as ACHV invests in development and commercialization; they rose from $10.2 million in the first quarter of 2026 to $74.8 million in the second. Funding for the Phase 3 trial and commercialization is in place, while the U.S. manufacturing transition has reached early steps, including a completed technology transfer and first engineering batch. The next results remain a risk to watch after an earnings miss, and a CFO transition was announced in October.

What Achieve Life Sciences Inc hinges on

Over the next few quarters, the thesis depends on advancing the Phase 3 trial and commercialization while managing losses and completing the manufacturing transition. A guidance cut would be a meaningful negative; stronger results and guidance from healthcare sector leaders could support a more favorable sector backdrop, though that is not specific proof of ACHV’s execution.